Repligen Corporation (RGEN) DCF Valuation

Repligen Corporation (RGEN) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Repligen Corporation (RGEN) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Discover the true value of Repligen Corporation (RGEN) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and evaluate how changes affect Repligen Corporation's (RGEN) valuation – all within one easy-to-use Excel template.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 270.2 366.3 670.5 801.5 638.8 826.9 1,070.5 1,385.9 1,794.2 2,322.7
Revenue Growth, % 0 35.53 83.08 19.54 -20.31 29.46 29.46 29.46 29.46 29.46
EBITDA 58.4 101.6 211.6 246.9 127.8 217.9 282.0 365.1 472.7 611.9
EBITDA, % 21.62 27.75 31.55 30.81 20 26.35 26.35 26.35 26.35 26.35
Depreciation 20.9 27.1 38.4 51.0 68.6 62.7 81.2 105.2 136.1 176.2
Depreciation, % 7.72 7.39 5.73 6.36 10.73 7.59 7.59 7.59 7.59 7.59
EBIT 37.6 74.6 173.1 195.9 59.2 155.1 200.8 260.0 336.5 435.7
EBIT, % 13.9 20.36 25.82 24.45 9.27 18.76 18.76 18.76 18.76 18.76
Total Cash 528.4 717.3 603.8 623.8 751.3 773.8 1,001.7 1,296.8 1,678.9 2,173.4
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 43.7 71.4 117.4 116.2 124.2
Account Receivables, % 16.16 19.49 17.51 14.5 19.44
Inventories 54.8 95.0 184.5 238.3 202.3 223.5 289.4 374.6 485.0 627.8
Inventories, % 20.29 25.94 27.51 29.73 31.67 27.03 27.03 27.03 27.03 27.03
Accounts Payable 11.4 16.9 36.2 27.6 19.6 34.3 44.4 57.5 74.4 96.3
Accounts Payable, % 4.23 4.61 5.4 3.44 3.06 4.15 4.15 4.15 4.15 4.15
Capital Expenditure -23.2 -26.3 -71.3 -133.3 -39.0 -81.3 -105.2 -136.2 -176.3 -228.2
Capital Expenditure, % -8.57 -7.19 -10.63 -16.64 -6.1 -9.83 -9.83 -9.83 -9.83 -9.83
Tax Rate, % 35.17 35.17 35.17 35.17 35.17 35.17 35.17 35.17 35.17 35.17
EBITAT 30.8 75.4 144.6 166.3 38.4 128.8 166.7 215.8 279.4 361.7
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -58.6 13.7 -4.4 22.7 88.0 83.9 44.6 57.7 74.7 96.7
WACC, % 8.55 8.62 8.56 8.56 8.49 8.55 8.55 8.55 8.55 8.55
PV UFCF
SUM PV UFCF 278.2
Long Term Growth Rate, % 4.00
Free cash flow (T + 1) 101
Terminal Value 2,208
Present Terminal Value 1,465
Enterprise Value 1,743
Net Debt -40
Equity Value 1,783
Diluted Shares Outstanding, MM 56
Equity Value Per Share 31.62

What You Will Receive

  • Adjustable Forecast Inputs: Effortlessly modify assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Repligen Corporation’s financial data pre-loaded to facilitate your analysis.
  • Automated DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
  • Customizable and Professional: A refined Excel model that caters to your valuation requirements.
  • Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.

Key Features

  • Comprehensive RGEN Data: Pre-loaded with Repligen’s historical financial performance and future forecasts.
  • Customizable Assumptions: Modify revenue growth rates, profit margins, discount rates, tax implications, and capital investments.
  • Interactive Valuation Framework: Automatically recalculates Net Present Value (NPV) and intrinsic value based on your specifications.
  • Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
  • Intuitive Interface: Designed for ease of use, catering to both seasoned professionals and newcomers.

How It Works

  • 1. Download the Template: Obtain and open the Excel file with Repligen Corporation’s (RGEN) preloaded data.
  • 2. Adjust Key Inputs: Modify essential parameters such as growth rates, WACC, and capital expenditures.
  • 3. Instant Results: The DCF model automatically computes intrinsic value and NPV in real-time.
  • 4. Explore Different Scenarios: Evaluate various forecasts to understand different valuation results.
  • 5. Present with Assurance: Deliver professional valuation analysis to back your strategic decisions.

Why Choose This Calculator for Repligen Corporation (RGEN)?

  • Accurate Data: Up-to-date Repligen financials provide dependable valuation outcomes.
  • Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
  • Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
  • User-Friendly: Easy-to-navigate interface and clear instructions make it accessible for all users.

Who Should Use This Product?

  • Investors: Evaluate Repligen Corporation’s (RGEN) market position before making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts for Repligen Corporation.
  • Startup Founders: Discover the valuation strategies employed by established companies like Repligen Corporation.
  • Consultants: Provide comprehensive valuation analyses and reports for clients interested in Repligen Corporation.
  • Students and Educators: Utilize real-time data from Repligen Corporation to enhance learning and teaching of valuation practices.

What the Template Contains

  • Historical Data: Includes Repligen Corporation’s past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Repligen Corporation’s intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Repligen Corporation’s financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.